Oprisine (Azathioprine)

Azathioprine, the active ingredient in Oprisine, is an immunosuppressant presented as a tablet for oral use. It is employed to prevent organ rejection and to manage autoimmune conditions in adults and children. GNH USA supplies Oprisine as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres and pharmacies worldwide.

GNH USA supplies Oprisine as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres and pharmacies worldwide.

Azathioprine is used across several immune‑mediated pathways to control abnormal immune activity.

- Prevention of organ transplant rejection: helps maintain graft function by suppressing immune response. - Autoimmune hepatitis: reduces liver inflammation and improves biochemical markers. - Rheumatoid arthritis: alleviates joint inflammation and slows disease progression. - Inflammatory bowel disease (Crohn’s disease and ulcerative colitis): diminishes intestinal inflammation and maintains remission. - Systemic lupus erythematosus: moderates systemic immune activation and organ involvement.

Azathioprine may cause a range of adverse reactions, from mild to potentially life‑threatening.

Common Side Effects: - Nausea and vomiting: occasional gastrointestinal upset. - Elevated liver enzymes: mild, transient increases in hepatic enzymes. - Leukopenia: reduced white‑blood‑cell count, often mild. - Rash or mild skin irritation: occasional dermatologic reaction. - Fatigue: general feeling of tiredness. - Mild headache: occasional cephalic discomfort.

Serious or Rare Side Effects: - Severe bone‑marrow suppression: profound pancytopenia requiring medical intervention. - Hepatotoxicity: significant liver injury with jaundice or elevated transaminases. - Opportunistic infections: increased susceptibility to bacterial, viral or fungal infections. - Malignancies: heightened risk of lymphomas and skin cancers with long‑term use. - Pancreatitis: inflammation of the pancreas presenting with abdominal pain. - Severe hypersensitivity reactions: including Stevens‑Johnson syndrome or drug‑induced fever.

Azathioprine requires careful monitoring and patient education before and during therapy.

- Baseline testing: obtain complete blood count and liver function tests prior to initiation. - Regular monitoring: schedule periodic CBC and liver panels to detect toxicity early. - Infection risk: advise patients to report fever, cough or unexplained infections promptly. - Pregnancy and lactation: discuss potential risks and consider alternative therapies when possible. - Drug interactions: review concomitant medications for possible synergistic myelosuppression. - Store at ambient temperature: keep tablets in original container, protect from moisture and direct sunlight.

Azathioprine interacts with several medicines that can alter its efficacy or safety profile.

Major Interactions (Avoid): - Allopurinol and febuxostat: increase risk of bone‑marrow suppression. - Ribavirin: additive myelosuppressive effect. - Live vaccines: heightened risk of infection due to immunosuppression.

Moderate Interactions (Monitor Closely): - Warfarin: may enhance anticoagulant effect, requiring INR monitoring. - ACE inhibitors: potential for increased nephrotoxicity. - Anticonvulsants (e.g., phenytoin): may affect azathioprine metabolism. - NSAIDs: can worsen renal function when combined with azathioprine.